Main content

    Hematologic Oncology Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov



    Leukemia  |  Lymphoma  |  Multiple Myeloma


    Active Trials

    Leukemia

    Title: A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies
    Description: This study is to evaluate the efficacy, safety, tolerability, and pharmacodynamics of entospletinib
    Investigator: Caroline Behler, MD
    Eligibility: Subjects, 18 y/o and older, who have a diagnosis of elapsed or refractory chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), or non-FL indolent non-Hodgkin lymphomas
    Status: Active and open to enrollment
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study Gilead 0102

    Back to top

    Lymphoma

    Title: Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
    Description: This randomized phase II trial studies how well rituximab and combination chemotherapy with or without lenalidomide work in treating patients with newly diagnosed stage II-IV diffuse large B cell lymphoma
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, who have hstologically confirmed DLBCL expressing cluster of differentiation (CD)20 antigen
    Status: Call site for study status
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study E1412

    Back to top

    Multiple Myeloma

    Title: A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
    Description: This randomized phase II trial studies how well two doses of carfilzomib work with dexamethasone in treating patients with relapsed or refractory multiple myeloma
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, who have a confirmed diagnosis of symptomatic multiple myeloma and must be relapsed or refractory
    Status: Contact site for study status
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study SWOG S1304

    Title: Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma
    Description: This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well it works compared to carfilzomib, lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, who are diagnosed with symptomatic standard-risk multiple myeloma (SR-MM)
    Status: Call site for study status
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study ECOG E1A11

    Title: Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
    Description: This phase II/III trial studies how well lenalidomide works and compares it to observation in treating patients with asymptomatic high-risk smoldering multiple myeloma
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, who are diagnosed with asymptomatic high-risk smoldering multiple myeloma (SMM) within the past 60 months
    Status: Call site for study status
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study ECOG E3A06

    Title: A Phase III Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM). (KEYNOTE 183)
    Description: The purpose of this study is to compare the efficacy of pomalidomide and low dose dexamethasone with pembrolizumab (MK-3475) to that of pomalidomide and low dose dexamethasone without pembrolizumab in terms of Progression-Free Survival (PFS) in participants with refractory or relapsed and refractory multiple myeloma (rrMM) who have undergone at least 2 lines of prior treatment
    Investigator: Ari Baron, MD
    Eligibility: Subjects, 18 y/o and older, who have a confirmed diagnosis of active multiple myeloma and measurable disease and who have undergone prior treatment with ≥2 treatment lines of anti-myeloma therapy and must have failed last line of treatment (refractory to last line of treatment)
    Status: Active and open to enrollment
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study Merck MK3475-183

    Title: A Phase III Study of Lenalidomide and Low-dose Dexamethasone With or Without Pembrolizumab (MK3475) in Newly Diagnosed and Treatment naïve Multiple Myeloma (KEYNOTE 185)
    Description: The purpose of this study is to compare the efficacy of lenalidomide and low dose dexamethasone with pembrolizumab (MK-3475) to that of lenalidomide and low dose dexamethasone without pembrolizumab in terms of progression-free survival (PFS) in participants with newly diagnosed and treatment-naïve multiple myeloma who are ineligible for autologous stem cell transplant (Auto-SCT)
    Investigator: Ari Baron, MD
    Eligibility: Subjects, 18 y/o and older, with a confirmed diagnosis of active multiple myeloma and measurable disease and who are ineligible to receive treatment with auto-SCT due to age, (≥65 years of age) or coexisting medical condition; participants <65 years of age who refuse auto-SCT are not eligible for this study
    Status: Active and open to enrollment
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study Merck MK3475-185

    • updated June 2016

    Back to top